Marketed therapeutic antibodies compendium

Area of Science:

• Biotechnology
• Pharmacology
• Immunology

Background:

• Therapeutic monoclonal antibodies (mAbs) are increasingly approved globally.
• Physicians and patients face challenges tracking mAb details like targets and approvals.
• This review focuses on mAbs approved in Europe and the US by March 2012.

Discussion:

• A comprehensive list of 34 therapeutic mAbs approved by March 2012 in Europe/US is presented.
• Details on production cell lines, antigenic targets, and approval dates are crucial for tracking.
• Six previously approved but withdrawn/discontinued mAbs are also included for historical context.

Key Insights:

• 28 out of 34 mAbs were actively marketed in Europe or the US as of March 2012.
• Nimotuzumab, approved outside Europe/US, is also discussed.
• The data provides a snapshot of the therapeutic mAb landscape at a specific point in time.

Outlook:

• Continued growth in mAb approvals necessitates robust tracking systems.
• Future reviews should include updated approval data and market status.
• Understanding the lifecycle of therapeutic mAbs is vital for drug development and clinical practice.